REG - IP Group PLC - Artios completes oversubscribed $115m financing

IPAnnouncement

17/11/2025 13:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251117:nRSQ8430Ha&default-theme=true

RNS Number : 8430H  IP Group PLC  17 November 2025

 FOR RELEASE ON  17 November 2025

 

Portfolio company Artios completes oversubscribed $115m Series D financing
round

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in
breakthrough science and innovation companies with the potential to create a
better future for all, is pleased to note that portfolio company Artios Pharma
Ltd ("Artios" or "the Company") has completed an oversubscribed funding round
totalling $115m.

 

Artios, which is developing next-generation approaches in the DNA damage
response (DDR) field in cancer, will use the funds to expand the clinical
evaluation of its lead program, alnodesertib, to enroll additional
ATM-negative patients in each of second-line pancreatic cancer and third-line
colorectal cancer, for which the program was recently granted U.S. FDA Fast
Track Designation. Proceeds will also be used to initiate a Phase 2 randomized
clinical trial for Artios' second potential first-in-class candidate, ART6043,
in patients with BRCA-mutant HER2-negative breast cancer who are eligible to
receive a PARP inhibitor.

 

IP Group invested £5.5m from its balance sheet to the financing round and,
following completion, has an undiluted beneficial holding of 6.8% in Artios.
The round was co-led by existing investor SV Health Investors and new investor
RA Capital Management, with participation from additional new investor Janus
Henderson Investors and broad support from Artios' existing investors.

 

Greg Smith, Chief Executive of IP Group, said: "We have backed Artios for
almost a decade and are delighted to see such strong support from both new and
existing investors in this funding round. Artios exemplifies the UK's strength
in life sciences and its potential to deliver world-leading breakthroughs with
real commercial promise."

 

The full announcement follows:

 

Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate
Clinical Programs in Indications of High Unmet Need

 

Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer
in ATM-negative patients for Artios' potential first-in-class ATR Inhibitor,
alnodesertib

Following encouraging ESMO data presentation, Artios will initiate a
randomized Phase 2 study for potential first-in-class Polθ inhibitor,
ART6043, in breast cancer

Financing co-led by SV Health and new investor, RA Capital Management, with
participation from new investor Janus Henderson Investors alongside existing
investors

 

 

CAMBRIDGE, United Kingdom and NEW YORK, November 17, 2025 - Artios Pharma
Limited ("Artios"), a biopharmaceutical company committed to realizing the
therapeutic power of targeting the DNA damage response ("DDR") in cancer,
today announced the successful close of an oversubscribed $115 million Series
D financing. The round was co-led by founding investor SV Health Investors and
new investor RA Capital Management, with participation from new investor Janus
Henderson Investors and broad support from Artios' existing investors.

 

The Series D proceeds will expand the clinical evaluation of Artios' lead
program, alnodesertib, to enroll additional ATM-negative patients in each of
second-line pancreatic cancer and third-line colorectal cancer, for which the
program was recently granted U.S. FDA Fast Track Designation. At the AACR
meeting in April 2025, Artios reported that alnodesertib, in combination with
low-dose irinotecan, demonstrated a 50% confirmed overall response rate in
patients with ATM-negative solid tumors at the recommended Phase 2 dose in the
STELLA Phase 1/2a trial. There are currently no approved therapies
specifically for patients whose tumors harbor ATM-deficiency, a population
where alnodesertib has demonstrated durable responses across eight different
solid tumors.

 

The proceeds from the financing will also be used to initiate a Phase 2
randomized clinical trial for Artios' second potential first-in-class
candidate, ART6043, in patients with BRCA-mutant HER2-negative breast cancer
who are eligible to receive a PARP inhibitor. The DNA polymerase Theta (Polθ)
inhibitor, ART6043, demonstrated an attractive tolerability profile, expected
PK/PD activity, and promising clinical signals in data from a Phase 1/2a study
presented at the ESMO Congress in September 2025. The company is also
advancing a first-in-class and highly differentiated DDR inhibitor-Antibody
Drug Conjugate (DDRi-ADC) program and expects to name a lead candidate in Q1
2026.

 

"This Series D accelerates our potential path to registration for both
alnodesertib and ART6043, broadening development for the next generation of
DNA damage response (DDR) therapeutics to indications among the highest of
unmet need across pancreatic, colorectal, and breast cancers, where median
survival is often measured in months," said Mike Andriole, Chief Executive
Officer of Artios. "As we address these indications and prepare for others, I
would like to thank our existing investors, led by SV Health, for their
ongoing support, and also our new investors, RA Capital Management and Janus
Henderson Investors, for joining our mission to bring these potential
medicines to patients as quickly as possible."

 

Nikola Trbovic, Managing Partner, SV Health Investors, added, "We are thrilled
to have supported Artios' evolution, from an early-stage DDR pioneer when we
founded the company to the established company it has become, distinguished by
a promising and differentiated pipeline. We look forward to continuing to do
so as it deploys the Series D proceeds to drive late-stage development of
alnodesertib as well as its pipeline. This financing, and the recent
appointment of Mike Andriole as CEO, are exciting steps in Artios' continued
growth and its transition toward becoming a commercially oriented
organization."

 

Jake Simson, Partner, RA Capital Management, commented, "We are excited to
co-lead this financing round to advance the next generation of DNA damage
response therapeutics. Artios' differentiated clinical programs, alnodesertib
and ART6043, together have the potential to meaningfully expand the impact of
DDR-targeted therapies. The rate and durability of responses observed to date
for alnodesertib across a range of solid tumors and the early clinical results
with ART6043 underscore the strength of Artios' approach and ability to
deliver novel, potentially first-in-class treatments for patients while
building significant long-term value."

 

The investors who supported the Series D round include Andera Partners,
Avidity Partners, EQT Life Sciences, Invus, IP Group plc, Janus Henderson
Investors, M Ventures, Novartis Venture Fund, Omega Funds, Pfizer Ventures,
Piper Heartland, RA Capital Management, Sofinnova Partners, Schroders Capital,
and SV Health Investors.

 

About Artios Pharma Ltd.

Artios is pioneering next-generation approaches in the DNA damage response
(DDR) field through its comprehensive anti-cancer approach and the deep
experience of its team of DDR drug developers. The company's clinical-stage
candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Polθ)
inhibitor ART6043, as well as its pre-clinical programs, including DDRi-ADCs,
are designed with differentiated pharmaceutical properties and novel
biological approaches to precisely eliminate a cancer cell's remaining
survival mechanisms. Artios' mission is to develop new classes of medicines
that exploit DDR pathways with the aim of improving outcomes for patients with
hard-to-treat cancers.

 

Visit our website at www.artios.com (http://www.artios.com) to learn more
about the company.

 

About SV Health Investors

SV Health Investors is a leading healthcare fund manager committed to
investing in tomorrow's healthcare breakthroughs. The SV funds invest across
stages, geographic regions, and sectors, with expertise spanning
biotechnology, dementia, medical devices, healthcare growth and healthcare
technology. With approximately $2bn in assets under management and a truly
transatlantic presence with offices in London and Boston, SV has built an
extensive network of talented investment professionals and experienced
industry veterans. Since its founding in 1993, SV has invested in, created and
built more than 200 companies attracting global talent, entrepreneurs and
pharma partners. To date, these investments have resulted in the licensing of
28 novel drugs and six new drug classes able to treat indications with unmet
medical needs and deliver positive impact to patients.

 

For more information, please visit www.svhealthinvestors.com
(http://www.svhealthinvestors.com) .

 

About RA Capital Management

Founded in 2004, RA Capital Management is a multi-stage investment manager
dedicated to evidence-based investing in public and private healthcare, life
sciences, and planetary health companies. RA Capital creates and funds
innovative companies, from private seed rounds to public follow-on financings,
allowing management teams to drive value creation from inception through
commercialization and beyond. RA Capital's knowledge engine is guided by its
dedicated internal research division; and Raven, RA Capital's healthcare
incubator, offers entrepreneurs and innovators a collaborative and
comprehensive platform to explore the novel and the re-imagined. RA Capital
has more than 170 employees and over $10 billion in assets under management.
Learn more at www.racap.com.

 

Media Inquiries

Trophic Communications

Jacob Verghese

Tel: +49 151 7441 6179

Email: artios@trophic.eu

 

(1)ATM protein levels determined by immunohistochemistry and depicted on an
H-score scale: ATM negative = 0; ATM low = 1-50; H-score scale goes from 0 to
300

 

For more information, please contact:

 

 IP Group plc                       www.ipgroupplc.com
 Liz Vaughan-Adams, Communications  +44 (0) 20 7444 0062/+44 (0) 7967 312125
 Portland
 Alex Donaldson                     +44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most
active UK based, early stage science investor, we develop and support some of
the world's most exciting businesses in deeptech, life sciences and cleantech.
Through Parkwalk, the UK's largest growth EIS fund manager, we also back
world-changing innovation emerging in leading universities and research
institutions. Our specialist investment team combines sector expertise with an
international approach. Together we have a strong track record of success,
having backed high-profile companies including Oxford Nanopore Technologies
plc, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on
the Main Market of the London Stock Exchange under the code IPO. For more
information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com/) .

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBRBTTMTABBIA



            Copyright 2019 Regulatory News Service, all rights reserved